Patent US2293704A successfully refreshed from Google Patents.
Patent US5447724A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5447724A Expired / Lapsed US ⏱️ 0.0 years remaining

Medical device polymer

Assignee: Harbor Medical Devices Inc
•
Filing: 1993-11-15
•
Granted: 1995-09-05
•
Expires: 2013-11-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A medical device and a method for its manufacture. The function of the medical device requires exposure of the device to the tissue of a patient. The device has a tissue-exposed portion constructed to release an agent that inhibits adverse reaction to the presence of the device defined by a polymeric surface-layer overlying in a supported manner a polymer defining a reservoir. The reservoir incorporates the agent in a manner that permits substantially free outward release of the agent from the reservoir and the overlying layer defines metering outward passages constructed to control the outward migration of the agent to enable prolonged release of the agent from the surface of the medical device to prevent the adverse reaction due to the presence of the device.

Inventors

  • 👤 Michael N. Helmus
  • 👤 M. Joshua Tolkoff
  • 👤 Carol L. Raleigh

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 12:48
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0047; A61L27/00; A61L27/50; A61L27/54; A61L33/0011; A61L33/007; A61M; A61M31/00; A61M31/002; A61L2300/00; A61L2300/20; A61L2300/22; A61L2300/222; A61L2300/23; A61L2300/236; A61L2300/40; A61L2300/404; A61L2300/412; A61L2300/414; A61L2300/416; A61L2300/42; A61L2300/60; A61L2300/606; A61L2300/608; A61M5/00; A61M5/14; A61M5/142; A61M5/14244; A61M5/14276

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 441 words
A medical device at least a portion of which comprises: a body insertable into a patient, said body having an exposed surface which is adapted for exposure to tissue of a patient and constructed to release, at a predetermined rate, a therapeutic agent adapted to inhibit adverse physiological reaction of said tissue to the presence of the body of said medical device, said therapeutic agent selected from the group consisting of antithrombogenic agents, antiplatelet agents, prostaglandins, thrombolytic drugs, antiproliferative drugs, antirejection drugs, antimicrobial drugs, growth factors, and anticalcifying agents, at said exposed surface, said body including: an outer polymer metering layer, and an internal polymer layer underlying and supporting said outer polymer metering layer and in intimate contact therewith, said internal polymer layer defining a reservoir for said therapeutic agent, said reservoir formed by a polymer selected from the group consisting of polyurethanes and its copolymers, silicone and its copolymers, ethylene vinylacetate, thermoplastic elastomers, polyvinylchloride, polyolefins, cellulosics, polyamides, polytetrafluoroethylenes, polyesters, polycarbonates, polysulfones, acrylics, and acrylonitrile butadiene styrene copolymers, said outer polymer metering layer having a stable, substantially uniform, predetermined thickness covering the underlying reservoir so that no portion of the reservoir is directly exposed to body fluids and incorporating a distribution of an elutable component which, upon exposure to body fluid, elutes from said outer polymer metering layer to form a predetermined porous network capable of exposing said therapeutic agent in said reservoir in said internal polymer layer to said body fluid, said elutable component is selected from the group consisting of polyethylene oxide, polyethylene glycol, polyethylene oxide/polypropylene oxide copolymers, polyhydroxyethylmethacrylate, polyvinylpyrollidone, polyacrylamide and its copolymers, liposomes, albumin, dextran, proteins, peptides, polysaccharides, polylactides, polygalactides, polyanhydrides, polyorthoesters and their copolymers, and soluble cellulosics, said reservoir defined by said internal polymer layer incorporating said therapeutic agent in a manner that permits substantially free outward release of said therapeutic agent from said reservoir into said porous network of said outer polymer metering layer as said elutable component elutes from said polymer metering layer, said predetermined thickness and the concentration and particle size of said elutable component being selected to enable said outer polymer metering layer to meter the rate of outward migration of the therapeutic agent from said internal reservoir layer through said outer polymer metering layer. said outer polymer metering layer and said internal polymer layer, in combination, enabling prolonged controlled release, at said predetermined rate, of said therapeutic agent at an effective dosage level from said exposed surface of said body of said medical device to the tissue of said patient to inhibit adverse reaction of the patient to the prolonged presence of said body of said medical device in said patient.
Claim 2
Dependent Claim 441 words
A medical device at least a portion of which comprises: a body insertable into a patient, said body having an exposed surface which is adapted for exposure to tissue of a patient and constructed to release, at a predetermined rate, a therapeutic agent adapted to inhibit adverse physiological reaction of said tissue to the presence of the body of said medical device, said therapeutic agent selected from the group consisting of antithrombogenic agents, antiplatelet agents, prostaglandins, thrombolytic drugs, antiproliferative drugs, antirejection drugs, antimicrobial drugs, growth factors, and anticalcifying agents, at said exposed surface, said body including: an outer polymer metering layer, and an internal polymer layer underlying and supporting said outer polymer metering layer and in intimate contact therewith, said internal polymer layer defining a reservoir for said therapeutic agent, said reservoir formed by a polymer selected from the group consisting of polyurethanes and its copolymers, silicone and its copolymers, ethylene vinylacetate, thermoplastic elastomers, polyvinylchloride, polyolefins, cellulosics, polyamides, polytetrafluoroethylenes, polyesters, polycarbonates, polysulfones, acrylics, and acrylonitrile butadiene styrene copolymers, said outer polymer metering layer having a stable, substantially uniform, predetermined thickness covering the underlying reservoir so that no portion of the reservoir is directly exposed to body fluids and incorporating a distribution of an elutable component which, upon exposure to body fluid, elutes from said outer polymer metering layer to form a predetermined porous network capable of exposing said therapeutic agent in said reservoir in said internal polymer layer to said body fluid, said elutable component is selected from the group consisting of polyethylene oxide, polyethylene glycol, polyethylene oxide/polypropylene oxide copolymers, polyhydroxyethylmethacrylate, polyvinylpyrollidone, polyacrylamide and its copolymers, liposomes, albumin, dextran, proteins, peptides, polysaccharides, polylactides, polygalactides, polyanhydrides, polyorthoesters and their copolymers, and soluble cellulosics, said reservoir defined by said internal polymer layer incorporating said therapeutic agent in a manner that permits substantially free outward release of said therapeutic agent from said reservoir into said porous network of said outer polymer metering layer as said elutable component elutes from said polymer metering layer, said predetermined thickness and the concentration and particle size of said elutable component being selected to enable said outer polymer metering layer to meter the rate of outward migration of the therapeutic agent from said internal reservoir layer through said outer polymer metering layer. said outer polymer metering layer and said internal polymer layer, in combination, enabling prolonged controlled release, at said predetermined rate, of said therapeutic agent at an effective dosage level from said exposed surface of said body of said medical device to the tissue of said patient to inhibit adverse reaction of the patient to the prolonged presence of said body of said medical device in said patient.
Claim 3
Dependent Claim 18 words
The medical device of claim 1 wherein said reservoir is a coating less than about 100 mils thick.
Claim 4
Dependent Claim 16 words
The medical device of claim 1 wherein said reservoir is about 2 to 3 mils thick.
Claim 5
Dependent Claim 18 words
The medical device of claim 1 wherein said polymer metering layer is less than about 100 mils thick.
Claim 6
Dependent Claim 16 words
The medical device of claim 4 wherein said surface-layer is about 2 to 3 mils thick.
Claim 7
Dependent Claim 41 words
The medical device of claim 1 wherein said outer polymer metering surface-layer and internal polymer layer are constructed for prolonged release of the therapeutic agent for a period corresponding to the duration of said exposure of said body to said tissue.
Claim 8
Dependent Claim 45 words
The medical device of claim 1 wherein said outer polymer metering surface-layer and internal polymer layer are constructed for release at levels effective to inhibit adverse reaction of the patient to the presence of said body in said patient for at least about 200 hours.
Claim 9
Dependent Claim 22 words
The medical device of claims 1 or 7 wherein said reservoir includes more than about 30% by weight of said therapeutic agent.
Claim 10
Dependent Claim 20 words
The medical device of claim 8 wherein said reservoir includes about 40 to 60% by weight of said therapeutic agent.
Claim 11
Dependent Claim 15 words
The medical device of claim 1 wherein said reservoir includes a non-physiologically active elutable component.
Claim 12
Dependent Claim 12 words
The medical device of claim 1 wherein said antithrombogenic drug is heparin.
Claim 13
Dependent Claim 26 words
The medical device of claim 1 wherein said therapeutic agent is in particulate form with a particle size about the thickness of said reservoir or less.
Claim 14
Dependent Claim 19 words
The medical device of claim 12 wherein said therapeutic agent is of less than about 10 micron particle size.
Claim 15
Dependent Claim 23 words
The medical device of claim 1 wherein said outer polymer metering layer includes less than about 20% by weight of said elutable component.
Claim 16
Dependent Claim 23 words
The medical device of claim 14 wherein said outer polymer metering layer includes about 10 to 20% by weight of said elutable component.
Claim 17
Dependent Claim 17 words
The medical device of claim 1 wherein said elutable component comprises colloidal regions in said surface layer.
Claim 18
Dependent Claim 15 words
The medical device of claim 16 wherein said elutable component colloidal regions are polyethylene oxide.
Claim 19
Dependent Claim 19 words
The medical device of claim 17 wherein said polyethylene oxide has a molecular weight of less than about 100,000.
Claim 20
Dependent Claim 13 words
The medical device of claim 1 wherein said elutable component comprises particulate regions.
Claim 21
Dependent Claim 15 words
The medical device of claim 1 wherein said elutable component includes a physiologically active agent.
Claim 22
Dependent Claim 29 words
The medical device of claim 1 wherein said elutable component includes a minor amount of said physiologically active agent prior to exposure of said exposed surface to said tissue.
Claim 23
Dependent Claim 24 words
The medical device of claim 1 wherein said elutable components create regions of about 50 microns or less in said first polymer metering surface-layer.
Claim 24
Dependent Claim 17 words
The medical device of claim 22 wherein said elutable components create regions about 10 microns or less.
Claim 25
Dependent Claim 13 words
The medical device of claim 23 wherein said elutable components create submicron regions.
Claim 26
Dependent Claim 13 words
The medical device of claim 1 wherein said device is a blood oxygenator.
Claim 27
Dependent Claim 33 words
The medical device of claim 1 wherein said outer polymer metering surface-layer covers the entire exposed surface of said body and said internal polymer layer is coextensive with said outer polymer metering surface-layer.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-09-04 1999-03-06 1999-09-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-09-04 2003-03-06 2003-09-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-09-04 2007-03-06 2007-09-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag